Literature DB >> 8145128

A mathematical model for dynamics of cardiovascular drug action: application to intravenous dihydropyridines in healthy volunteers.

P Francheteau1, J L Steimer, H Merdjan, M Guerret, C Dubray.   

Abstract

A physiologically based mathematical model was built to describe the pharmacodynamic effects in response to the administration of intravenous (iv) dihydropyridine drugs in healthy volunteers. This model incorporates a limited number of hemodynamic variables, namely, mean arterial blood pressure (MAP), cardiac output (CO) or heart rate (HR), stroke volume (SV), and total peripheral resistance (TPR), into a closed-loop system supposed to represent essential features of the cardiovascular regulation. We also defined an additional auxiliary control variable (U) which is thought to represent primarily the role of the baroreceptor reflex. It was assumed that the variable U was related to MAP changes through both deviation- and rate-sensitive mechanisms. Other model parameters are the baseline levels for MAP, CO (or HR), and TPR, as well as time constants to account for further temporal aspects of the regulation. Finally, TPR was assumed to be linked to the plasma concentrations of dihydropyridine drugs via a conventional pharmacokinetic/pharmacodynamic (PK/PD) model, relying upon an effect compartment and a linear, hyperbolic, or sigmoidal relationship between the reduction in TPR and the drug concentrations at the effect site. The model characteristics were explored by studying the influence of various parameters, including baseline levels and deviation- and rate-sensitive control parameters, on the hemodynamic responses to a fictive constant rate i.v. infusion of a vasodilator drug. Attempts were also made to mimic literature data with nifedipine, following i.v. administration under both constant and exponentially decreasing infusion rates. The applicability of the model was demonstrated by fitting hemodynamic data following i.v. infusion of nicardipine to healthy volunteers, under experimental conditions similar to those described above for nifedipine. The effect model for the action of nicardipine on TPR, combined with the physiological model including a feedback control loop, allowed an adequate quantitative description of time profiles for both cardiac output and mean arterial pressure. The suggested model is a useful tool for integrated data analysis of hemodynamic responses to vasodilator drugs in healthy volunteers. Computer simulations suggest that a graded variation of a few model parameters--including baseline levels of TPR and MAP and the deviation-sensitive parameter of the arterial pressure control--would also be able to account for the pattern of hemodynamic response observed in hypertensive patients, which is qualitatively different to that seen in normotensive subjects. Extrapolation of drug response from the healthy volunteer to the hypertensive patient is allowed by our model. Its usefulness for an early evaluation of drug efficacy during drug development is under current investigation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8145128     DOI: 10.1007/bf01059111

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  28 in total

Review 1.  Reflexes from the heart.

Authors:  R J Liden
Journal:  Prog Cardiovasc Dis       Date:  1975 Nov-Dec       Impact factor: 8.194

Review 2.  Pharmacodynamic modelling. Application to new drug development.

Authors:  P D Kroboth; V D Schmith; R B Smith
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

3.  Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model.

Authors:  R J Francis; A N Brown; L Kler; T Fasanella d'Amore; J Nussberger; B Waeber; H R Brunner
Journal:  J Cardiovasc Pharmacol       Date:  1987-01       Impact factor: 3.105

4.  Capillary column gas chromatographic method using electron-capture detection for the simultaneous determination of nicardipine and its pyridine metabolite II in plasma.

Authors:  A T Wu; I J Massey; S Kushinsky
Journal:  J Chromatogr       Date:  1987-03-20

5.  The use and abuse of models.

Authors:  A Rescigno; J S Beck
Journal:  J Pharmacokinet Biopharm       Date:  1987-06

6.  Diminished baroreflex sensitivity in high blood pressure.

Authors:  J D Bristow; A J Honour; G W Pickering; P Sleight; H S Smyth
Journal:  Circulation       Date:  1969-01       Impact factor: 29.690

7.  Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data.

Authors:  C C Peck; S L Beal; L B Sheiner; A I Nichols
Journal:  J Pharmacokinet Biopharm       Date:  1984-10

Review 8.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

9.  Parameter and structural identifiability concepts and ambiguities: a critical review and analysis.

Authors:  C Cobelli; J J DiStefano
Journal:  Am J Physiol       Date:  1980-07

10.  Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans.

Authors:  C H Kleinbloesem; P van Brummelen; M Danhof; H Faber; J Urquhart; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1987-01       Impact factor: 6.875

View more
  15 in total

Review 1.  Interchangeability and predictive performance of empirical tolerance models.

Authors:  M Gårdmark; L Brynne; M Hammarlund-Udenaes; M O Karlsson
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

2.  Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers.

Authors:  Meindert Danhof; Gunnar Alvan; Svein G Dahl; Jochen Kuhlmann; Gilles Paintaud
Journal:  Pharm Res       Date:  2005-08-24       Impact factor: 4.200

3.  Model-based decision making in early clinical development: minimizing the impact of a blood pressure adverse event.

Authors:  Mark Stroh; Carol Addy; Yunhui Wu; S Aubrey Stoch; Nazaneen Pourkavoos; Michelle Groff; Yang Xu; John Wagner; Keith Gottesdiener; Craig Shadle; Hong Wang; Kimberly Manser; Gregory A Winchell; Julie A Stone
Journal:  AAPS J       Date:  2009-02-06       Impact factor: 4.009

4.  PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious rats.

Authors:  N Snelder; B A Ploeger; O Luttringer; D F Rigel; R L Webb; D Feldman; F Fu; M Beil; L Jin; D R Stanski; M Danhof
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

5.  A tutorial on model informed approaches to cardiovascular safety with focus on cardiac repolarisation.

Authors:  S Y A Cheung; J Parkinson; U Wählby-Hamrén; C D Dota; Å M Kragh; L Bergenholm; T Vik; T Collins; C Arfvidsson; C E Pollard; H K Tomkinson; B Hamrén
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-05-07       Impact factor: 2.745

6.  Semi-mechanistic modelling platform to assess cardiac contractility and haemodynamics in preclinical cardiovascular safety profiling of new molecular entities.

Authors:  Raja Venkatasubramanian; Teresa A Collins; Lawrence J Lesko; Jerome T Mettetal; Mirjam N Trame
Journal:  Br J Pharmacol       Date:  2020-06-18       Impact factor: 8.739

7.  Relationship between hypoglycaemic response and plasma concentrations of BTS 67 582 in healthy volunteers.

Authors:  W D Byrom; N E Rotherham; J R Bratty
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

8.  Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling.

Authors:  N Snelder; B A Ploeger; O Luttringer; D F Rigel; F Fu; M Beil; D R Stanski; M Danhof
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 9.  The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.

Authors:  J S Grundy; R T Foster
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

10.  Clinical trial simulation using therapeutic effect modeling: application to ivabradine efficacy in patients with angina pectoris.

Authors:  Sylvie Chabaud; Pascal Girard; Patrice Nony; Jean-Pierre Boissel
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-08       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.